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Abstract: Groups of rhesus macaques that had previously been immunized with HIV-1
envelope (env) peptides and first generation adenovirus serotype 5 (FG-Ad5) vaccines
expressing the same peptides were immunized intramuscularly three times with helperdependent adenovirus (HD-Ad) vaccines expressing only the HIV-1 envelope from JRFL.
No gag, pol, or other SHIV genes were used for vaccination. One group of the FG-Ad5immune animals was immunized three times with HD-Ad5 expressing env. One group was
immunized by serotype-switching with HD-Ad6, HD-Ad1, and HD-Ad2 expressing env.
Previous work demonstrated that serum antibody levels against env were significantly
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higher in the serotype-switched group than in the HD-Ad5 group. In this study,
neutralizing antibody and T cell responses were compared between the groups before and
after rectal challenge with CCR5-tropic SHIV-SF162P3. When serum samples were
assayed for neutralizing antibodies, only weak activity was observed. T cell responses
against env epitopes were higher in the serotype-switched group. When these animals were
challenged rectally with SHIV-SF162P3, both the Ad5 and serotype-switch groups
significantly reduced peak viral loads 2 to 10-fold 2 weeks after infection. Peak viral loads
were significantly lower for the serotype-switched group as compared to the
HD-Ad5-immunized group. Viral loads declined over 18 weeks after infection with some
animals viremia reducing nearly 4 logs from the peak. These data demonstrate significant
mucosal vaccine effects after immunization with only env antigens. These data also
demonstrate HD-Ad vectors are a robust platform for vaccination.
Keywords: HIV-1; SHIV; adenovirus; helper-dependent vector; mucosal challenge;
serotype-switching

1. Introduction
The development of an effective HIV-1 vaccine is essential for controlling the HIV-1 pandemic.
However, this goal has been difficult to accomplish due to the inherent biology of the virus including,
but not limited to its propensity to infect immune cells and undergo high rates of mutation. A number
of vaccine approaches are being developed to elicit these responses including live/attenuated HIV or
SIV [1,2]; viral vectors including pox-, alpha-, and adenovirus vectors [3-7]; genetic
immunization [8-10], peptide vaccines [11,12], and virus-like particle (VLP) vaccines [13-16].
It has been estimated that as much as 90% of HIV-1 infections occur by sexual transmission. In
these cases, infection is thought to occur in most cases at vaginal, rectal, and urethral mucosal surfaces
(reviewed in [17]). Given that the mucosal surface is the predominant entry route for HIV-1, there has
been increasing interest in the development of vaccines that can generate robust antibody and cellular
responses at mucosal surfaces (reviewed in [18]). Despite the recognized need for mucosal protection,
most non-human primate challenge models involve intravenous injection of SIV or SHIV into animals.
While this is appropriate to test the quality of systemic vaccination, this vaccine-challenge may not
address whether mucosal protection is produced.
Adenoviral (Ad) vectors are one of the most robust gene-based vaccine vectors available [19-24].
Until recently, most adenoviral vaccine experiments have utilized the well-studied human adenovirus
serotype 5 Ad (Ad5). While this virus is one of the most robust at generating anti-HIV immune
responses, the majority of the human population has been exposed to this virus and have pre-existing
neutralizing antibodies that can attenuate vaccine delivery [25]. While pre-existing antibodies are a
problem, once an Ad vaccine is introduced into a non-immune host, this itself will provoke an antivector response that will quench subsequent use of this vaccine.
One approach to evade neutralizing antibodies is to “serotype switch” the vector by changing the
serotype of the Ad vaccine at each administration [26,27]. When applied for HIV vaccines, serotype-
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switching evades vector-induced immunity allowing robust prime-boost vaccination with different
adenoviruses [28-32].
In most cases, Ad serotype-switching has been performed using first generation adenoviral (FG-Ad)
vectors. We recently demonstrated proof of principle for the use of helper-dependent adenoviral (HDAd) vectors for serotype-switching in mice and non-human primates [33]. In HD-Ad vectors, all viral
sequences are deleted from the vector with the exception of the inverted terminal repeats (ITRs) and
packaging signal needed to replicate and package the vector. This allows sequences as large as 35
kilobase pairs to be packaged [34,35]. Because all adenoviral genes have been removed from the
vector, no Ad proteins are expressed after vector delivery. Therefore, HD-Ad vectors generate lower
vector-specific immune responses [36-38].
The HD-Ad system easily allows serotype switching, since Ads in the same species can crosspackage each other’s genomes. We recently utilized species C Ad helper viruses from serotypes 1, 2,
5, and 6 to cross-package HD-Ad5 vectors expressing reporter genes or HIV-1 env [33]. By this
approach, we demonstrated the HD-Ad vectors generated lower anti-vector immune responses and
allowed multiple rounds of prime-boost against HIV-1 env in mice and in FG-Ad5-immune rhesus
macaques [33].
In this work, we have mucosally challenged these HD-Ad-immunized macaques by rectal
administration of the CCR5-tropic virus SHIV-SF162P3 [39]. We provide data on T cell and
neutralizing antibody immune responses to complement our previous report on ELISA antibody
responses against env. We also provide data on the effects on viral loads in the animals by repeated
HD-Ad5 vaccination versus serotype-switch HD-Ad6, 1, and 2 vaccination.
2. Results and Discussion
2.1. Immunizations Prior to HD-Ad Vaccinations
Eight macaques from previous studies (Table 1) were used in these experiments to conserve
animals and for their prior immunizations with FG-Ad5 vectors. These animals had originally been
immunized with various formulations of a synthetic peptide vaccine consisting of six conserved
epitopes in the envelope (env) protein that have previously been shown to be effective at priming HIVspecific cellular immune responses in multiple animal models and humans [11,40-44]. These six
peptides shown aligned to env in Figure 1 generate CD4 and CD8 responses without generating
antibody responses. These peptides in various formulations mediate protection in macaques vs. SHIVKU2 and SHIV-89.6P [43,44]. Prior to the HD-Ad study, macaques Rh51, Rh55, Rh62, and Rh63 had
been vaccinated with the six synthetic peptides adjuvanted with FLT-3 ligand, CpG and by loading on
dendritic cells (Table 1). Macaques Rh52, Rh61, Rh66, and Rh67 received a similar course with the
exception of receiving an inactivated cholera toxin adjuvant (CT2*) rather than FLT-3 ligand and CpG
(Table 1).
These animals were selected for study with HD-Ad, since they had all previously been vaccinated
twice by the nasal route with 1011 virus particles (v.p.) of FG-Ad5 expressing a fusion protein of the
six peptides (vector described in [45]). Therefore, these animals represented an Ad5 pre-immune
population on which to test the utility of HD-Ad serotype-switching. While this was advantageous,
prior immunizations with the six env peptides could affect T cell responses against these six epitopes
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that might be generated by the HD-Ad vaccines, but should not affect T cell responses outside these
regions (Figure 1). Likewise, since the peptide vaccines do not generate antibodies against env, they
would not be expected to confuse antibody effects of the HD-Ad vaccines.
Figure 1. Protein sequence alignment of envelope antigens used in this study. The JRFL
gp140 immunogen expressed by the HD-Ad vectors was aligned to the SF162P3 env
protein of the challenge virus. Boxes indicate the locations of the six env peptides that
were used to vaccinate the macaques prior to HD-Ad vaccination.
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Table 1. Vaccines Used in the Macaques in this Study.

Macaque

Rh51
Rh55
Rh52
Rh61
Rh62
Rh63
Rh66
Rh67

Env peptides
+ FL3L +
CpG
3X
12/2006
+
+

Env peptides
+ CT2*
3X

Ad-EnvPep
nasal
2X

Env Peptides HD-Ad5-Env HD-Ad6-Env
HD-Ad1-Env
+ DCs
2X
3X
HD-Ad2-Env

12/2006

12/2007
+
+
+
+
+
+
+
+

3/2008
+
+
+
+
+
+
+
+

+
+
+
+
+
+

9/2008
+
+
+
+

9/2008

+
+
+
+

Dates shown designate when each vaccine was applied to the indicated animals.

2.2. HD-Ad Vaccinations
The macaques in this study were only vaccinated with env immunogens. No gag, pol, or other
SHIV sequences were used. The JRFL gp140 env antigen in the Ad vaccines was generated by
deletion of the furin cleavage site between gp120 and gp41 and deletion of the transmembrane domain.
This immunogen therefore does not immunize against epitopes that are present in the cleavage and
transmembrane domains in the SHIV-SF162P3 challenge virus. Alignment of the JRFL immunogen
with the SF162P3 antigen shows 545 identical amino acids and 47 divergent amino acids within the
common peptide sequences (Figure 1). Therefore, JRFL immunogen has 89% identity with the
challenge virus.
Macaques Rh51 and Rh55 from the FLT group and animals Rh52 and Rh61 from the CT2* group
were utilized for HD-Ad5 vaccination (Table 1). Monkeys Rh62 and Rh63 from the FLT group and
macaques Rh66 and Rh67 from the CT2* group were used for HD-Ad6, 1, and 2 vaccination. Each
group of four macaques were immunized at days 0, 24, and 67 with 1011 vp of the indicated HD-Ads
expressing the JRFL gp140 form of env (Figure 1) by i.m. injection. Group 1 received HD-Ad5 three
times. Group 2 received HD-Ad6, then HD-Ad1, then HD-Ad2 at the same time points.
2.3. Neutralizing Antibodies Generated Against HIV-1 Envelope
We previously reported on the antibody responses against env by ELISA [33]. This work revealed
that FG-Ad5-immune animals that were immunized with only HD-Ad5-Env generated only minimal
responses. In contrast, immunization with HD-Ad6-Env, HD-Ad1-Env, and HD-Ad2-Env generated
detectable anti-env antibodies at each immunization with final antibody levels being 10-fold higher
than in the HD-Ad5 group (p < 0.01) [33]. Given the high ELISA antibody responses, the samples
were sent to the Immune Monitoring Core supervised by Dr. David Montefiori at Duke University to
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assess if these antibodies could neutralize SHIV or HIV viruses in vitro (Table 2). By this assay, only
slight neutralization titers were observed when the samples were tested against SHIV-SF162P4 viruses
and 89.6P.18, but not against other test viruses. Other field isolates tested were: SHIV-SF162P3.5,
JRFL/293T, 6535.3, QH0692.42, SC422661.8 and PVO.4.
Table 2. Neutralizing Antibodies vs. SHIV.
ID50 in TZM-bl cells1
Animal

51

52

55

61

62

63

66

67

1

Bleed

SHIV-SF162P4

SHIV-89.6P.18

day

(ID#762)

(ID#767)

0

<20

<20

24

<20

<20

57

<20

<20

83

<20

<20

0

36

20

24

25

<20

57

<20

<20

83

25

<20

0

31

<20

24

23

<20

57

<20

<20

83

55

23

0

25

<20

24

<20

<20

57

22

<20

83

<20

<20

0

<20

<20

24

<20

<20

57

<20

<20

83

<20

<20

0

25

<20

24

<20

<20

57

<20

<20

83

25

<20

0

<20

<20

24

<20

<20

57

<20

<20

83

22

<20

0

<20

<20

24

<20

<20

57

<20

<20

83

46

<20

Values are the sample dilution at which relative
luminescence units (RLUs) were reduced 50% compared
to virus control wells (no test sample).
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2.4. Neutralizing Antibodies Against Adenovirus
Ad5 neutralizing antibody levels were monitored in the animals after each immunization (Figure 2).
Before first HD-Ad immunization, Ad5 neutralizing titers were 28 for the HD-Ad5 group and 52 for
the serotype-switch group. This demonstrated that the prior intranasal FG-Ad5 immunizations had
produced anti-Ad5 immunity in the animals. After first HD-Ad immunization, HD-Ad5 and HD-Ad6
boosted Ad5 neutralization titers to 500 in both groups. Two more immunizations with HD-Ad5
increased final titers to 800. One immunization with HD-Ad1 and then one with HD-Ad2 produced
declining anti-Ad5 antibody levels that were three-fold lower than those generated by three HD-Ad5
immunizations. These data indicate that other viruses in species C can boost common neutralizing
antibody levels (i.e. HD-Ad6), but that serotype-switching ultimately reduces the level of neutralizing
antibodies after three immunizations.
Figure 2. Neutralizing Antibody Responses Against Ad. Plasma samples taken at the
indicated times were incubated with Ad5 expressing luciferase for 1 hour at 37°C prior to
addition to A549 cells. 24 hours later, luciferase activity was measured and gene delivery
was compared to untreated Ad5 vector. Data is expressed as geometric mean titers that
reduced Ad luciferase activity 50%.

2.5. T Cell Responses Generated by the HD-Ad Vaccines
PBMCs were harvested before and after each vaccination to monitor T cell responses against the
env antigen by ELISPOT. PBMCs were stimulated either with the six epitopes of the peptide vaccine
that was delivered prior to Ad vaccination or with overlapping 15-mer peptide pools from HIV-1
SF162P3 env covering the gp140 region in the HD-Ad vectors. Alignment of the JRFL gp140
immunogen with SF162P3 peptide pools shows 89% identity with the peptides used for ELISPOT.
Alignment with of JRFL with the peptide vaccine shows amino acid mismatches in four of the six
peptides (Figure 1).
ELISPOT testing before HD-Ad vaccination revealed responses below background for two
macaques in the HD-Ad6/1/2 group and three in the HD-Ad5 group (Figure 3). The three other
macaques had weak ELISPOT signals of 200 or less SFCs per 106 cells (Figure 3). With each HD-Ad

Viruses 2009, 1

927

immunization, CD8-IFN- SFCs generally increased in both groups when after stimulation with the
SF162P3 env overlapping peptide pools. Responses were higher against the SF162P3 peptides in all of
the serotype-switched animals and were less variable than in the HD-Ad5 group. T cell responses
peaked after one or two immunizations in the HD-Ad5 group with peaks from 200 to 800 SFCs per 106
cells. In contrast, T cell responses peaked in most serotype-switched animals after third immunization
with highest SFCs ranging from 700 to 2,000 SFCs (Table 3). When the six peptides of the peptide
vaccine were used to stimulate the PBMCs, SFC responses in both groups were substantially lower
and less frequent (Figure 3), suggesting that most of the T cell responses were directed at epitopes
outside those covered by the peptide vaccine (Figure 1). Stimulation of the PBMCs with Ad5 or Ad6
produced largely undetectable T cell responses suggesting responses were predominantly against the
env immunogen rather than against the Ad vectors.
Figure 3. IFN- ELISPOT of PBMCs from macaques during HD-Ad vaccination and after
SHIV challenge. PBMCs were stimulated with SF162P3 env peptide pools, the six
conserved env peptides, or Ad5 or Ad6 viruses. Spot forming cells (SFC) as measured by
ELISPOT are shown relative to the y axis, with the time point of assay before and after
vaccination and challenge shown below each graph. The HD-Ad5 group is shown in lower
panels and the serotype-switched (HD-Ad6, 1, 2) group is shown in the top panels. On the
x-axis, HD-Ad designates time points 2 weeks after each vaccination. Arrows indicate the
time of SHIV challenge. SHIV+2, SHIV+4, and SHIV+18 designate weeks 2, 4, and 18
after SHIV challenge.
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Table 3. Total anti-SF162P3 ELISPOT responses.

Values represent the combined ELISPOT responses to all 3 pools of overlapping peptides with pre-HD-Ad immune
responses subtracted. Bold values indicate peak cellular anti-SF162P3 immune responses.

2.6. Mucosal SHIV Challenge
To mimic sexual transmission of HIV, macaques were challenged by atraumatic administration of
1,000 TCID50 of the CCR5-tropic virus SHIV-SF162P3 (Figure 4). Challenge of three control
macaques produced peak viremia within 2 weeks with viral loads above 2x107 viral genomes per ml of
plasma (Figure 4B). Viral loads remained above 106 copies/ml for 6 months at which time two of the
animals were sacrificed due to weight loss and AIDS-like symptoms.
Figure 4. Plasma viral loads after rectal SHIV-SF162P3 challenge. Three control
macaques and the eight HD-Ad vaccinated macaques were challenged rectally by
atraumatic administration of 1,000 TCID50 of SHIV-SF162P3. Viral loads were assessed
by quantitative realtime PCR of viral genomes from the blood at the indicated times after
challenge. A) Viral loads over 18 weeks after challenge. B) Comparison of peak viral titers
at 2 weeks after challenge. Rh51 was excluded from the analysis due to high probability
that the animal was not infected with SHIV rather than sterilizing immunity was generated.
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Figure 4. Cont.

The HD-Ad-immunized animals were challenged 4 months after first immunization. This SHIVSF162P3 challenge produced lower peak viremia and viral set points (Figure 4). At peak, viral loads
were 2 to 10-fold lower in the HD-Ad vaccinated group than in control animals. One animal Rh51 in
the HD-Ad5 group had viral RNA levels below detection and so appeared to have not had a "take" of
the challenge virus. When Rh51 was censored, peak viremia at 2 weeks for both vaccine groups was
significantly lower than controls (p = 0.04, Figure 4B). Notably, peak viremia for the HD-Ad6/1/2
group was significantly lower than the HD-Ad5/5/5 group (p < 0.05). By 18 weeks, viral set points
were below 3,000 copies for all of the immunized macaques. This was notable, since all of these
animals were only vaccinated with env antigens. No gag or other SHIV antigens were used. While the
HD-Ad5/5/5 and HD-Ad6/1/2 groups were not significantly different from each other at this time, it
was interesting that that the viral RNA levels for Rh55 from the HD-Ad5 group and Rh63 and Rh67
from the HD-Ad6/1/2 group were down to 30-60 eq./ml or 4 orders of magnitude down from their
peak viremia.
2.7. Discussion
We previously reported the use of HD-Ad vectors for HIV vaccination [33]. In this earlier work, we
were able to utilize eight macaques that had previously been immunized nasally with FG-Ad5 to test
our ability to vaccinate in Ad5-immune macaques. We demonstrated that serotype-switching did
indeed provide robust circumvention of pre-existing immunity in these non-human primates and
allowed the production of anti-env antibody responses that were 9 times higher than those generated
by HD-Ad5 vectors [33].
In this work, we have analyzed the production of neutralizing antibodies against the env transgene
protein and against Ad5 itself. This work shows that the strong anti-env ELISA titers that we observed
after serotype-switching unfortunately did not translate into the production of robust neutralizing
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antibodies against HIV or SHIV. These data suggest that protection was mediated by T cell responses
or by other antibody mechanisms (i.e. antibody-dependent cellular cytotoxicity (ADCC) [46], etc.).
This is consistent with previous observations that SHIV-SF162P3 is notoriously hard to neutralize with
antibodies [47,48].
While these Ad5 pre-immune animals provided a good model to test for antibody production alone,
they had also been previously been vaccinated with the six env peptides in various formats (Table 1).
Since these peptide vaccines do not generate antibody responses, this did not affect comparison of env
antibody production by the HD-Ad vaccines, but could affect the production of T cell responses by
acting as priming vaccines for the HD-Ad vaccines. To test this, we compared PBMC ELISPOT
responses against the cognate six epitopes used in the previous vaccinations and against overlapping
15-mer peptides from SF162P3 env spanning the vaccine's gp140 region. This comparison revealed
that there was little cross-reactivity generated by the HD-Ad vaccines against the six peptides, but
stronger T cell responses were generated against the peptide pools. These data suggest that the HD-Ad
vaccines are generating much of the detectable T cell responses observed in the macaques.
While prior immunization with the peptides complicated data analysis, in the interest of the strong
responses we observed and to minimize future animal use, we opted to challenge these animals with
SHIV. We performed mucosal challenge by the rectal route with the CCR5-tropic virus SHIVSF162P3 to mimic sexual transmission of the virus. While SIV is arguably a more suitable mucosal
challenge virus than SHIV, our challenge virus had to express an HIV-1 env to assess the HIV-1 envdirected immunity that the HD-Ad vaccines had established. This challenge demonstrated that control
animals had severe peak viremia after mucosal challenge and that this viremia persisted for six months
until AIDS-like symptoms necessitated euthanasia of two of the animals. In contrast to controls, the
HD-Ad vaccinated animals had 2 to 10-fold lower peak viremia and viral loads generally trended
downward over the next 4 months. For three of the animals, viral loads approached the limits of
detection by 18 weeks. These data suggest that the peptide vaccines, the HD-Ad vaccines, or both lead
to lower viral loads in the animals after mucosal challenge. Given the observed ELISPOT responses,
we speculate that much of this protection was mediated by the Ad vaccines.
Comparison of the HD-Ad5/5/5-immunized animals and the serotype-switched HD-Ad6/1/2 group
demonstrated that animals vaccinated with the different serotypes had statistically lower peak viremia
than those immunized with only HD-Ad5. This confirms the utility of serotype-switching that has
previously been observed using FG-Ad vectors [28-32]. This also suggests that some level of the
protection against SHIV challenge was actually mediated by the Ad vectors rather than the earlier
peptide vaccines, since the serotype-switched vaccine generated more robust immune responses that
may have resulted in the lower peak and set point viral loads. Peak cellular responses in the HDAd6/1/2 serotype-switched group were observed after the third immunization for three of the four
immunized animals. This indicates that serotype-switching was driving anamnestic responses while the
HD-Ad5/5/5 group immune responses may have become senescent due to increasing anti-Ad5
neutralizing antibodies (Fig. 2 and Table 3). This comparison is based on censoring Rh51 from the
analysis, since it had undetectable viral loads throughout the study. Censoring this animal is based on
the assumption that the undetectable viral loads in HD-Ad5/5/5 group monkey Rh51 were due to poor
"take" of the challenge virus. If Rh51 is included, the two groups are equal to each other by statistical
comparison. While it is formally possible that the vaccine fully protected Rh51, we are unaware of an
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example of sterilizing immunity being generated by any vaccine in this model. In addition, T cell and
antibody responses in Rh51 were comparable to those in other macaques. Therefore, the most likely
explanation is that Rh51 merely was not robustly infected by the challenge virus.
3. Experimental Section
3.1. Adenoviruses
HD-Ad1, 2, 5, and 6 viruses expressing the gp140 form of HIV-1 JRFL were produced as
previously described [33]. HD-Ad5-env vector was transfected into a 60-mm dish of Cre-expressing
116 cells expressing Cre recombinase as in [49]. The transfected cells were infected a day later with
the E1-deleted Ad5 helper virus AdNG163 whose packaging signal is flanked by loxP sites [49] for
deletion in the Cre cells. Lysates were subsequently amplified by serial infections with AdNG163 in
116 cells. CsCl-banded HD-Ad were then produced from 3 liters of 116 cells producing HD-Ad preps
with E1 -deleted helper contamination less than 0.02% [49]. HD-Ad1, 2, and 6 vectors were generated
with helper viruses Ad1LC8cCEVS-1, Ad2LC8cCARP [26], and Ad6LC8cCEVS-6, respectively that
were generously provided by Carole Evelegh and Frank L. Graham (McMaster University).
3.2. Animals
All animal experiments were carried out according to the provisions of the Animal Welfare Act,
PHS Animal Welfare Policy, and the principles of the NIH Guide for the Care and Use of Laboratory
Animals, and the policies and procedures of the University of Texas MD Anderson Cancer Center.
Eleven adult male rhesus macaques (Macaca mulatta) of Indian origin were maintained in the specific
pathogen-free breeding colony at the Michael Keeling Center for Comparative Medicine and Research
of The University of Texas MD Anderson Cancer Center, Bastrop TX. The animals were anesthetized
during procedures to minimize discomfort. The animals were not screened for Mamu genotype prior to
study, but were randomized into the two HD-Ad vaccine groups based to equally segregate animals
previously treated into both groups.
3.3. Immunizations Prior to HD-Ad Vaccinations
Eight macaques from previous studies (Table 1) were used in these experiments. These animals had
originally been immunized with various adjuvanted synthetic peptide vaccines consisting of six
conserved env epitopes [11,40-44].
3.4. HD-Ad Vaccination
These peptide and FG-Ad5-immunized macaques were immunized at days 0, 24, and 67 with 1011
vp of the indicated HD-Ads by i.m. injection (Table 1).
3.5. Collection of Samples
Samples were collected at each time point indicated before any immunization or procedure.
Peripheral venous blood samples were collected in EDTA or sodium heparin. Before the separation of
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peripheral blood mononuclear cells (PBMC) from the blood samples, plasma was separated and stored
immediately at -80°C. Peripheral Blood Mononuclear Cells (PBMCs) were prepared from the blood on
Ficoll-Hypaque density-gradients.
3.6. Assay for Neutralization of HIV and SHIV
Neutralization was measured as a reduction in luciferase reporter gene expression after a single
round of infection in TZM-bl cells as described [50,51]. TZM-bl cells were obtained from the NIH
AIDS Research and Reference Reagent Program, as contributed by John Kappes and Xiaoyun Wu.
Briefly, 200 TCID50 of virus was incubated with serial 3-fold dilutions of test sample in duplicate in a
total volume of 150 l for 1 hr at 37oC in 96-well flat-bottom culture plates. Freshly trypsinized cells
(10,000 cells in 100 l of growth medium containing 75 g/ml DEAE dextran) were added to each
well. One set of control wells received cells + virus (virus control) and another set received cells only
(background control). After a 48 hour incubation, 100 l of cells was transferred to a 96-well black
solid plates (Costar) for measurements of luminescence using the Britelite Luminescence Reporter
Gene Assay System (PerkinElmer Life Sciences). Neutralization titers are the dilution at which
relative luminescence units (RLU) were reduced by 50% compared to virus control wells after
subtraction of background RLUs. Assay stocks of molecularly cloned Env-pseudotyped viruses were
prepared by transfection in 293T cells and were titrated in TZM-bl cells as described [50]. The clade
B reference Env clones were described previously [50].
3.7. Assay for Neutralization of Ad5
Ad5 neutralization was performed as described previously [45]. Briefly, serial dilutions of plasma
were incubated in triplicate for 1 hour at 37°C with Ad5 vector expressing luciferase. The resulting
solution was added to A549 cells for 24 hours and luciferase activity was measured. Data is expressed
as geometric mean titers that reduced Ad luciferase activity 50%.
3.8. ELISPOT assay for detecting antigen-specific IFN- producing cells
Freshly prepared PBMC were used for the IFN- ELISPOT assay as described previously [52].
PBMCs were either stimulated with synthetic peptides pools, with Ad expressing env, or with Con A
(5 g/ml) as positive control reagent. For the six peptide vaccine cocktail, the six epitopes (Figure 1)
were mixed as a pool. For overlapping envelope peptides, the SF162P3 env 15-mer peptide set (NIH
AIDS Reagent Program) was used as 3 pools of 50 to 70 peptides spanning the gp140 region.
Alignment of the JRFL immunogen encoded in the Ad vectors with SF162P3 peptide pool shows 89%
identity with the peptide pool used for ELISPOT. PBMCs (1 x 105) were seeded in duplicate wells of
96-well plates (polyvinylidene difluoride backed plates, MAIP S 45, Millipore, Bedford, MA) coated
with anti-IFN-The cells were incubated in the presence of the various antigens for 36 h at 37C. The
cells were then removed, the wells washed , and then incubated with 100 l of biotinylated anti-IFN-
for 3 h at 37C followed by avidin-HRP for another 30 minutes. Spots representing individual cells
secreting IFN- were developed using 0.3 mg/ml of 3-amino-9-ethyl-carbazole in 0.1 M sodium
acetate buffer, containing 0.015% hydrogen peroxide. The plates were washed to stop development
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and the spots were counted by an independent agency (Zellnet Consulting, New Jersey, NJ). The
responses in terms of IFN- spot forming cells (SFC) for 105 total input CD8+ T cells were determined
for individual monkeys after subtracting background values of cells cultured in the medium. The cut
off value for determining the positive response in the assay is defined as a minimum of 10 spots that is
twice the number observed in cells cultured in the medium. Data is represented as SFCs per 106
PBMCs for comparison to previous reports in the literature.
3.9. Virus Challenge
Macaques were challenged macaques by intrarectal inoculation of 1,000 TCID50 of SHIV-SF162P3
from the NIH AIDS Reagent Program.
3.10. Viral Load Determination
SHIV viral loads from the blood were determined by determining viral RNA copy numbers by realtime RT-PCR analyses. These assays were performed at the NIH Core Facility by Dr. Jeff Lifson's
group. The threshold sensitivity of the assay is 30 viral RNA copy-equivalents/ml of plasma, and the
inter-assay variation is <25% (coefficient of variation).
3.11. Statistical Analyses
Data was evaluated using GraphPad Prism 4 software. P values ≤ 0.05 were considered statistically
significant.
4. Conclusions
This study demonstrates that serotype-switched HD-Ad vaccines generate higher immune responses
and lower viral loads after mucosal challenge with a CCR5-tropic SHIV. This provides proof of
principle for applying these vaccines systemically or mucosally to repel mucosal entry by SIV or HIV1. These data are also notable given the fact that these non-human primates were only immunized with
the envelope immunogen. No gag, pol, nef, or other SIV or HIV proteins we used for vaccination. This
suggests that delivery of these missing lentiviral antigens by HD-Ad vaccines may well provide even
more substantial protection against mucosal challenge.
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